Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.

Standard

Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. / Sommer, Frank; Schulze, Wolfgang.

in: WORLD J UROL, Jahrgang 23, Nr. 6, 6, 2005, S. 385-392.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{2b1e6d9ecc0a4ceeb8e80fab364944d3,
title = "Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.",
abstract = "A large body of evidence has accumulated demonstrating that a common pathway in conditions such as hypertension, atherosclerosis, hypercholesterolemia, diabetes mellitus, and erectile dysfunction (ED) is endothelial dysfunction. Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Results from recent studies suggest that regular treatment with a PDE5 inhibitor may lead to enhanced erectile function (EF) beyond that observed with on-demand usage, possibly through improvement of endothelial function. Such an effect may be viewed as rehabilitation of damaged erectile tissue. The present review focuses on several recent studies which provide evidence for the beneficial effect of regular PDE5 inhibitor administration on the improvement of EF by rehabilitation of vascular endothelium.",
author = "Frank Sommer and Wolfgang Schulze",
year = "2005",
language = "Deutsch",
volume = "23",
pages = "385--392",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.

AU - Sommer, Frank

AU - Schulze, Wolfgang

PY - 2005

Y1 - 2005

N2 - A large body of evidence has accumulated demonstrating that a common pathway in conditions such as hypertension, atherosclerosis, hypercholesterolemia, diabetes mellitus, and erectile dysfunction (ED) is endothelial dysfunction. Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Results from recent studies suggest that regular treatment with a PDE5 inhibitor may lead to enhanced erectile function (EF) beyond that observed with on-demand usage, possibly through improvement of endothelial function. Such an effect may be viewed as rehabilitation of damaged erectile tissue. The present review focuses on several recent studies which provide evidence for the beneficial effect of regular PDE5 inhibitor administration on the improvement of EF by rehabilitation of vascular endothelium.

AB - A large body of evidence has accumulated demonstrating that a common pathway in conditions such as hypertension, atherosclerosis, hypercholesterolemia, diabetes mellitus, and erectile dysfunction (ED) is endothelial dysfunction. Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Results from recent studies suggest that regular treatment with a PDE5 inhibitor may lead to enhanced erectile function (EF) beyond that observed with on-demand usage, possibly through improvement of endothelial function. Such an effect may be viewed as rehabilitation of damaged erectile tissue. The present review focuses on several recent studies which provide evidence for the beneficial effect of regular PDE5 inhibitor administration on the improvement of EF by rehabilitation of vascular endothelium.

M3 - SCORING: Zeitschriftenaufsatz

VL - 23

SP - 385

EP - 392

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 6

M1 - 6

ER -